SCM
FNCH

SCS Capital Management’s Finch Therapeutics Group, Inc. Common Stock FNCH Stock Holding History

SCS Capital Management’s Portfolio FNCH Stock Details FNCH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,276
Closed -$64K – 65
2022
Q3 		$64K Hold
1,276
– – ﹤0.01% 58
2022
Q2 		$109K Hold
1,276
– – ﹤0.01% 58
2022
Q1 		$193K Hold
1,276
– – ﹤0.01% 54
2021
Q4 		$382K Buy
+1,276
New +$489K 0.01% 45

Other funds holding FNCH

Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
AMC
Avenir Management Company New York $43.8M AUM 101.91% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
LSAG
Lake Street Advisors Group Portsmouth, New Hampshire $2.17B AUM 16.99% 1-Year Est. Return
TA
TRB Advisors New York $146M AUM 3.71% 1-Year Est. Return
SW
SVB Wealth Boston, Massachusetts $1.59B AUM 24.57% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

SCS Capital Management's FNCH Position: Q4 2022 in Review

SCS Capital Management sold out of Finch Therapeutics Group, Inc. Common Stock (FNCH) in Q4 2022, closing a stake of 1,276 shares — an estimated $64K sold.

SCS Capital Management first reported a position in FNCH in Q4 2021 and held it in 4 quarters. The position peaked at $382K in Q4 2021. 40 funds tracked by Wall St. Rank hold FNCH as of Q4 2022.

  • SCS Capital Management reported no remaining Finch Therapeutics Group, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • SCS Capital Management sold 1,276 Finch Therapeutics Group, Inc. Common Stock shares in Q4 2022, an estimated $64K.
  • SCS Capital Management first reported a position in Finch Therapeutics Group, Inc. Common Stock in Q4 2021 and held it in 4 quarters.
  • SCS Capital Management's Finch Therapeutics Group, Inc. Common Stock position peaked at $382K in Q4 2021.
  • 40 funds tracked by Wall St. Rank held Finch Therapeutics Group, Inc. Common Stock as of Q4 2022.

Based on SCS Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.